The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval for AVT03, Alvotech's proposed biosimilar to Prolia and Xgeva. This positive opinion marks a significant regulatory milestone for the Icelandic biotech company, bringing the medication one step closer to European market availability. The recommendation covers both the 60 mg/mL pre-filled syringe formulation and the 70 mg/mL vial version of the denosumab biosimilar.

AVT03 functions as a human monoclonal antibody that targets the RANK ligand membrane protein, reducing osteoclast activity to decrease bone resorption. Prolia is indicated for treating osteoporosis in postmenopausal women and men at increased fracture risk, while Xgeva prevents bone complications in adults with advanced cancer that has spread to bone. The biosimilar approach aims to provide comparable therapeutic benefits while potentially increasing affordability and access.

Upon final approval by the European Commission, STADA Arzneimittel AG will market the biosimilar under the brand names Kefdensis for the 60 mg/mL formulation and Zvogra for the 70 mg/mL version. Dr. Reddy's Laboratories SA will offer corresponding products named Acvybra and Xbonzy. Both partners hold semi-exclusive commercial rights across Europe, including Switzerland and the United Kingdom.

Joseph McClellan, Alvotech's Chief Scientific and Technical Officer, stated that this development demonstrates how the company's specialized biosimilars platform enables broader access to affordable biologic medicines. The product remains under EMA regulatory review pending a final decision by the European Commission, which typically follows the CHMP's positive recommendation within several months.

A Swedish court has convicted six individuals for their involvement in the murder of a 41-year-old gang leader in the Berga district of Linköping during the summer of 2024. The Linköping District Court delivered verdicts in the case, which involved eight defendants originally charged with participation in the killing. The court established that the murder was carried out according to a criminal plan orchestrated by members of an organized crime network based in the Berga area.

The victim was fatally shot in a public space near Berga Church in Linköping on August 13, 2024. Multiple gunshots struck the man in his back and head during the daylight incident, which occurred near residential buildings and a playground. Several members of the public witnessed the shooting, adding to the evidence presented during the trial.

Court proceedings revealed that a 14-year-old boy fired the fatal shots that killed the gang leader. The teenager, who has admitted to the killing, was not prosecuted due to being below the age of criminal responsibility under Swedish law. Instead, prosecutors focused on the eight older individuals allegedly involved in planning and facilitating the murder, all of whom had denied the charges against them.

Evidence presented by prosecutors included extensive documentation of movement patterns through surveillance footage, GPS data from electric scooters, and mobile phone analysis. The court determined the victim had been lured to the crime scene under the pretense of a drug transaction, with communication occurring through a special Snapchat account and a dedicated mobile phone later found buried in nearby woods. Six of the eight defendants were found guilty, with two receiving life sentences for murder while others were convicted of aiding the killing.